沙美特罗替卡松联合噻托溴铵不同吸入装置给药治疗慢性阻塞性肺疾病的临床观察

发布时间：2018-10-08 08:09

【摘要】：目的:观察沙美特罗替卡松联合噻托溴铵不同吸入装置给药治疗慢性阻塞性肺疾病(COPD)患者的临床疗效和安全性。方法:选择2014年1月-2015年1月我院COPD患者80例,按照随机数字表法分为试验组和对照组,各40例。两组患者均给予沙美特罗替卡松粉吸入剂500μg,bid+噻托溴铵粉吸入剂18μg,qd,对照组患者使用药品自带吸入装置给药,试验组患者使用气体压缩式超声雾化吸入器给药。两组患者均治疗1年。观察两组患者给药0.5 h后的血药浓度,给药后第3、6、9个月的呼吸困难指数(m MRC)评分和COPD评估测试(CAT)评分,治疗期内急性加重次数,治疗前后1秒用力呼气容积占预计值的百分比(FEV1%),并记录不良反应发生情况。结果:试验组患者脱落4例,对照组患者脱落1例。给药0.5 h后,两组患者替卡松、沙美特罗和噻托溴铵的血药浓度比较,差异均无统计学意义(P0.05)。给药后,试验组患者m MRC评分略低于对照组,但差异无统计学意义(P0.05);CAT评分明显低于对照组,差异有统计学意义(P0.05)。试验组患者治疗期间急性加重次数明显少于对照组,差异有统计学意义(P0.05)。试验组患者的FEV1%下降值略低于对照组,但差异无统计学意义(P0.05)。试验组患者不良反应发生率明显低于对照组,差异有统计学意义(P0.05)。结论:沙美特罗替卡松联合噻托溴铵使用气体压缩式超声雾化吸入器给药治疗COPD患者的临床疗效和安全性均优于药品自带吸入装置给药。
[Abstract]:Aim: to observe the clinical efficacy and safety of salmeterol and tiotropium bromide in the treatment of patients with chronic obstructive pulmonary disease (COPD). Methods: 80 patients with COPD in our hospital from January 2014 to January 2015 were randomly divided into trial group and control group with 40 cases each. Two groups of patients were given salmeterol ticasone powder inhaler 500 渭 g bid tiotropium powder inhaler 18 渭 g / g QD, the control group patients were given drugs with their own inhaler, and the patients in the test group were treated with gas compression ultrasonic atomizer. Both groups were treated for 1 year. The blood concentration of the two groups, the (m MRC) score of dyspnea index at 6 and 9 months after administration, the (CAT) score of COPD evaluation test, and the times of acute exacerbation during the treatment period were observed. Forced expiratory volume as a percentage of predicted value (FEV1%) before and after treatment, and adverse reactions were recorded. Results: there were 4 cases in the test group and 1 case in the control group. After 0.5 h of administration, there was no significant difference in serum concentrations of ticasone, salmeterol and tiotropium between the two groups (P0.05). After administration, the score of m MRC in the trial group was slightly lower than that in the control group, but the difference was not statistically significant (P0.05) and the cat score was significantly lower than that in the control group (P0.05). The number of acute exacerbations in the trial group was significantly less than that in the control group (P0.05). The decrease of FEV1% in the trial group was slightly lower than that in the control group, but the difference was not statistically significant (P0.05). The incidence of adverse reactions in the trial group was significantly lower than that in the control group (P0.05). Conclusion: the clinical efficacy and safety of salmeterol combined with tiotropium bromide in the treatment of COPD patients with gas compression ultrasonic atomization inhaler is superior to that of drug self-contained inhaler.
【作者单位】：成飞医院呼吸内科;
【分类号】：R563.9

【相似文献】